Compare HNI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNI | NRIX |
|---|---|---|
| Founded | 1944 | 2009 |
| Country | United States | United States |
| Employees | N/A | 357 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 1994 | 2020 |
| Metric | HNI | NRIX |
|---|---|---|
| Price | $41.43 | $23.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $70.00 | $30.50 |
| AVG Volume (30 Days) | 840.3K | ★ 3.2M |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,839,000,000.00 | $76,987,000.00 |
| Revenue This Year | $117.19 | N/A |
| Revenue Next Year | $3.68 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.37 | ★ 99.31 |
| 52 Week Low | $28.93 | $8.20 |
| 52 Week High | $53.29 | $24.88 |
| Indicator | HNI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 77.28 | 77.77 |
| Support Level | $38.04 | $14.63 |
| Resistance Level | $47.51 | N/A |
| Average True Range (ATR) | 1.66 | 1.35 |
| MACD | 0.82 | 0.66 |
| Stochastic Oscillator | 97.78 | 84.37 |
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.